Insulin price cap fails to deliver affordable access
· audio
The Insulin Price Cap Mirage
The $35 per month cap on insulin prescriptions has failed to deliver significant improvements in affordability, despite widespread fanfare. Millions of people continue to struggle to afford their lifesaving medication.
Recent surveys and studies indicate that pharmaceutical greed remains a major obstacle to insulin accessibility. According to the Yale Diabetes Center’s research, nearly one-quarter of patients treated there in 2024 were rationing insulin due to cost concerns – a rate comparable to that seen in 2017. When insurance delays or supply limits are factored in, more than one-third (38 percent) of people struggled to maintain their medication.
The issue is not limited to individuals; it’s a symptom of deeper problems within the healthcare system. The $35 cap only applies to Medicare recipients, leaving millions of privately insured Americans vulnerable to exorbitant insulin costs. State laws capping out-of-pocket costs have significant loopholes that exempt large self-funded plans from state mandates.
A multifaceted approach is required to address this crisis, including drug pricing reform, insurance mandates, and possibly even public manufacturing. Out-of-pocket caps are inadequate for addressing the root causes of this issue.
Every new policy or law implemented seems to reveal more holes and loopholes in our system. We’ve seen this story before: each solution only provides temporary relief, masking deeper problems that persist. As Dr. Kasia Lipska noted, “It’s not as simple as just showing up at the pharmacy and asking for your insulin… It’s extremely complicated.” This complexity is a symptom of our broken healthcare system.
The diabetes community has been sounding the alarm on this issue for years. Policymakers and industry leaders must now listen to the data: we’re not making progress fast enough. A more comprehensive approach is needed – one that addresses systemic issues driving up insulin costs, rather than just providing temporary fixes.
The insulin price crisis serves as a microcosm of broader healthcare problems. It’s a reminder that even when we think we’ve made progress, individuals continue to struggle with basic necessities like medication. Until we address the root causes of this crisis, we’ll be stuck in an endless cycle of partial solutions and broken promises.
The stakes are high – not just for those living with diabetes but for our entire healthcare system. It’s time to stop patching up holes and start tackling underlying issues driving up costs. The future of healthcare depends on it.
Reader Views
- RSRiya S. · podcast host
The $35 insulin cap is a Band-Aid on a bullet wound. While it's laudable that policymakers are acknowledging the crisis, we're still treating symptoms rather than addressing systemic issues. The real problem lies in Big Pharma's stranglehold on the market, where manufacturers can dictate prices and gouge patients with impunity. Until we tackle this core issue, even caps and price controls will be nothing more than ineffective stopgap measures. We need to take a hard look at patent law reform and consider public manufacturing options to break the monopoly and make insulin affordable for all who need it.
- TSThe Studio Desk · editorial
While the $35 cap on insulin prescriptions was touted as a victory for affordability, its limitations are more telling than its symbolic gesture. One crucial aspect missing from this narrative is the role of pharmacy benefit managers (PBMs). These middlemen negotiate between insurers and manufacturers, often with opaque contracts that drive up costs without patients ever knowing. The true solution lies in reforming these PBMs and bringing transparency to their dealings – a step that's long overdue but still absent from policy debates.
- CBCam B. · audio engineer
The insulin price cap is a Band-Aid on a bullet wound - it's not addressing the root cause of the problem. We need to start talking about how these pharmaceutical companies are making a killing on insulin and what we can do to regulate their pricing. The article highlights the issue with out-of-pocket caps, but what really gets me is that many of these state laws exempt large self-funded plans from state mandates. This is where the real problem lies - we need to shine a light on how corporate greed is driving this crisis and start pushing for meaningful reform.